Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Shares Traded Last Trade
  1.00 0.63% 158.50 35,518 09:00:00
Bid Price Offer Price High Price Low Price Open Price
147.00 170.00 162.50 148.50 157.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.90 -1.07 -3.20 40
Last Trade Time Trade Type Trade Size Trade Price Currency
12:36:54 O 571 148.0001 GBX

Fusion Antibodies (FAB) Latest News (3)

More Fusion Antibodies News
Fusion Antibodies Investors    Fusion Antibodies Takeover Rumours

Fusion Antibodies (FAB) Discussions and Chat

Fusion Antibodies Forums and Chat

Date Time Title Posts
27/10/202013:24☆ Fusion Antibodies: from discovery to Clinical supply ☆724
17/10/202011:42NEW FAB Fusion Antibodies The Next AVCT52
18/9/202014:23Fusion Antibody II51
17/9/202008:25COVID. RAPID PROGRESS MADE. Ј3M RAISED58
08/2/201221:34Fabio Capello Resigns.......9

Add a New Thread

Fusion Antibodies (FAB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:36:55148.00571845.08O
12:36:42148.00571845.08O
11:29:14148.00169250.12O
10:09:09150.001,0001,500.00O
10:05:02148.007381,092.24O
View all Fusion Antibodies trades in real-time

Fusion Antibodies (FAB) Top Chat Posts

DateSubject
27/10/2020
08:20
Fusion Antibodies Daily Update: Fusion Antibodies Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FAB. The last closing price for Fusion Antibodies was 157.50p.
Fusion Antibodies Plc has a 4 week average price of 142.50p and a 12 week average price of 77.50p.
The 1 year high share price is 250p while the 1 year low share price is currently 54.50p.
There are currently 25,437,025 shares in issue and the average daily traded volume is 29,069 shares. The market capitalisation of Fusion Antibodies Plc is £40,317,684.63.
15/10/2020
08:19
superg1: It's why Fusion has longevity where test driven or co point parts Covid hope shares are on borrowed time. Antibody engineering type companies are a relatively new science. It seemed mad when Roche bought Genentech for $47 bill on a big premium. But they were right as the drugs they had grew in revenue EG over $20 bill of sales in 2018 alone. 7 of the top 10 drugs are now antibody related. The big names are snapping up the smaller Antibody engineering type companies. FAB seem to be a leader in the sector with and seriously impressive platform. So for me the Covid side has the potential to see a material share price hike short term, but the likely outcome, judging by what is going on in this sector, is that Fab will be acquired by a major. There is no better time to have a flag waving in Antibody engineering and skills. Fab were and are working with MAB discovery. MAB have since been acquired by BioNtech. FAB have made some big claims, a check of information available suggest they have every right to make the claims and expect the platform and their tech to be of enormous value. What is missing here is the herd jumping up and down about the share which they will probably know every little about, if they ever arrived. That's probably due to FAB being relatively quiet, not popping up in the usual interviews post every piece of news.
08/10/2020
17:28
superg1: So thinking longer term. I see Fusion as free bet on the Covid side as the share has not seen the rapid multiples on the share price like others. Covid on the other hand has raised the importance of such companies like Fusion in the siloed of antibodies. So Fusion could see a material rise in the share price on identifying Covid neutralising antibodies form the library but isn't sitting at a £400m plus market cap to fall off. Why Fusion lacks is repeated news and interviews about how exciting it could be and therefore it doesn't have the herd chasing it. If they do, there are very few shares available.
25/9/2020
10:00
tidy 2: Are Fusion on a pathway to finding the Holy Grail ?Fusion rapidly advancing their R&D MAL validation programme with successful SARS-CoV-2 antigens created for commercial use, moving onto the next step, finding a neutralising antibody for the disease.I meant to cover the news from Fusion Antibodies (FAB) last week when it was announced but the news landed whilst I was under the knife having my 5th, yes 5th eye operation ! Long story but I seem to be on the mend however my surgeon would probably be slapping my wrist if she knew I was at the PC right now !You can read more in-depth info on Fusion in my research notes Part 1 and Part 2 and it's well worth a read as even though the recent news was COVID related, that element is just one part of what the company are doing but obviously topical !The share price saw a whopping 180% intraday rise on the news that the company have produced SARS-CoV-2 spike proteins (antigens) that 100% correlate with patient blood samples for the disease and at the 250p intra-day high the share price was 150% up from the share price at the time I produced my research note back in May – not a bad return thus far!The following is an extract from the RNS...The Company's extensive antigen manufacturing capabilities means that Fusion has been able to express high-purity antigens on a commercially viable scale for the development of diagnostic tests. The Company is now offering these antigens on a commercial basis to companies and researchers worldwide. Unlike the PCR tests that are currently being used to identify the presence of COVID-19, Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19. This could be invaluable for disease modelling and public health policy, as it will assist in the determination of true transmission rates and case fatality rates.But the next phase of what they are doing gets even better...The Company has commenced use of these antigens to interrogate the Library for SARS-CoV-2 neutralising antibodies with a view to providing these as potential prophylactic and therapeutic candidatesThis last bit is of major interest, as I covered in my research note, the company are running an R&D programme to validate the Mammalian Antibody Library, the 'MAL' which has been in development for a few years.The opportunity...With the first few steps complete and successful if they can now use the MAL to identify neutralising antibodies for the high quality 100% correlated COVID spike proteins they have produced, the potential for a treatment for COVID that could stop the virus in its tracks would be HUGEWhilst the wider market seems to focus just on testing Pharma stocks, Fusion are at the heart of testing, diagnostics and potentially a treatment. Clearly the upside would be huge, caveated by the usual inherent complexities of drug development of course.As I have explained before though, Fusion aren't just about COVID-19, validation of the MAL would open opportunities in oncology and other healthcare applications and imagine if a large Pharma company wanted to snap up this technology for themselves to give them a firm competitive edge in getting to market faster.One can only wonder what such technology would be worth either outright or licensed to Pharma companies – either way I believe successful MAL validation opens the door for a potential $billion+ valuation.Given the company have a core business and this year returned 79% YOY revenue growth I see an excellent risk vs reward here with potentially transformative upside on offerhTTps://spongeshare.com/2020/09/23/are-fusion-on-a-pathway-to-finding-the-holy-grail/
24/9/2020
22:15
29palms: FAB share price on 17th Sept - 92.5p FAB share price on 18th Sept - 182.5p FAB RNS released @ 9:31am on 18th Sept and super Self Aggrandiser appears here @ 10.12am after rise in sp https://uk.advfn.com/cmn/fbb/thread.php3?id=42081683&from=173#firstpost True to form the super Self-Aggrandiser only ever appears on a BB thread once the share price goes stratospheric.
24/9/2020
14:53
superg1: Shareman Well that's all down to supply and demand of the shares and often doesn't relate to the value fo the company. I see underlying value here in the growing business to justify the share price. So the MC is about £50m. In 15 PE terms it's 59p on the share price for every £1m profits which equates to about £3.4 mill profit at £2 per share. Some Covid shares have tests, some tests strips, some in trials for symptoms reduction, some vaccine options. None I can think of have Covid neutralising options. Vaccines are fine but they are telling us immunity doesn't last. We have ha various scares, on other viruses. That is what FAB is all about a library to combat various viruses and added to exiting drugs to advance those. EG the world biggest seller at $20 bill year is an antibody type drug. So imo FAB had growth, low spending and huge revenue potential via the library and the platform including carrels in drugs already as yet not identified, 1 at least in stage 2.
22/9/2020
17:19
acuere: MMS need the Institutions to top slice and I’m sure some will be happy to oblige in what is a very illiquid stock. However there’s only so many they will sell at these levels so you can expect another share price surge on the back of the next positive Rns. I think there are a lot of punters sitting on the sidelines hoping for an share price pullback and it’s probably best for them to build a stake piecemeal and hope the share doesn’t surge in the meantime.
22/9/2020
09:20
superg1: XTomo The way I see it with FAB is that the underlying business is exciting and was before Covid appeared, it's just that Covid caused me to look. Typically I jog on on most companies especially Bios but I like the look of Fab. As posted a 15 PE equates to about 57p on the share price per £1m profit. There was a 79% increase re you revenues. The forecast was £3m revenue the actual was £3.9m Covid has now serials highlighted the crucial roll companies like Fab play. As stated they have a good brand reputation as 5 other companies failed to provide what a Pharma needed but FAB sorted it no problem. Fab are also working with a company created by Ex Roche bosses re the library as in news. FAB do not have the high spend re drugs trials, they ditched that business plan years ago. Sop far less risk but huge upside available makes it bio I like. In a sector where it's growing in interest and profit it enhances existing treatments in various sectors.
21/9/2020
08:55
superg1: On the MM front Wins are off the offer so what they had this morning has gone. So it would seem it's normal market conditions now PIs buying and selling which will determine which way it goes. The bounce timing directly correlates to when Wins moved off the offer. There were 3.3m shares in the raise at 90p About 1 mill of those went to a major holder, no other Tr1s appeared. One would trigger at 750k shares as that would be 3% So the others in the raise had less than that, some could have had 100k or less and jumped on the price spike for a quick profit, perhaps one of those is what Wins had this morning, perhaps left over from Friday. If you compare it to a Avacta the funds and about 90 mill cheap shares in the raise, but they waited some time before offloading. The FAB raise equated to 3.3m shares added the first raise in 3 years. 25.4 mill shares in issue will see the share price fly all over the place. Currently just 3 MMs with the normal market size limited to 3000 shares at the moment. In previous weeks/months there was virtually no volume. Fab is very difficult share to build a decent holding via the normal route.
20/9/2020
13:53
20pc: I was wondering why FAB released their RNS at 9:30 on Thursday. Hoping that FAB had been working with Roche and agreed to announce after Roche released their news on Thursday re Roche launches new quantitative antibody test … Which uses similar phrases to FAB. Thought it likely that FAB had worked with Roche in the past and confirmed here [...] “Some of the drugs it has worked on are going through phase I and II human trials, while another that Fusion contributed to has been patented by Swiss giant Roche. If it is the case then are the tests, using FAB antigens, already available from last Thursday. Roche link. hTTps://www.roche.com/investors/updates/inv-update-2020-09-18b.html Any views appreciated.
01/5/2020
05:50
ianb5004: POST ON LSE LAST NIGHT - THOUGHTS ? FAB vs HEMO. Thu 22:04 I have analysed both and FAB beats HEMO in every single area: FAB has lower Market Cap FAB has lower Free Float FAB is better Funded FAB is directly finding a Human Antibody using their tried and tested mammalian library vs HEMO which is a much slower process of testing in humanised rats FAB is already established with bluechip pharma companies that use them FABs business is underpinned through existing revenues FAB is Fabulous :-)
Fusion Antibodies share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
FAB
Fusion Ant..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201027 13:43:58